Skip to main content
Signal8
Launch Terminal

Prelude Therapeutics Inc (PRLD)

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Prelude Therapeutics Incorporated logo

Prelude Therapeutics Incorporated

NASDAQ:PRLDHealthcare
-5.37%$3.88
AH$3.85-0.77%vs close
Mkt Cap$309.64M
Float38.72M
O/S79.8M
Vol
$ Vol
RVOL
Inst Own62.1%
SI13.2%
Earnings
Dilution
Prelude Therapeutics Incorporated logoNASDAQ:PRLD$3.88-5.37%
Phase Distribution
13 lead-sponsored trials·1 active·8 completed
Phase 112
Phase 21
Status Overview
Not yet recruiting1
Recruiting1
Completed8
Stopped3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Terminated

    A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

    PRT3789, pembrolizumab

    Advanced Solid Tumor, Esophageal Cancer +3

    Enrollment
    6
    Start
    Jun 2025
    Primary Completion
    Jan 2026
    Completion
    Jan 2026
    NCT06682806
  • Phase 1
    Completed

    A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

    PRT543

    Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma +6

    Enrollment
    232
    Start
    Feb 2019
    Primary Completion
    Nov 2022
    Completion
    Nov 2022
    NCT03886831
  • Phase 1
    Completed

    A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

    PRT811

    Advanced Solid Tumor, Recurrent Glioma

    Enrollment
    86
    Start
    Nov 2019
    Primary Completion
    Mar 2023
    Completion
    Mar 2023
    NCT04089449
  • Phase 1
    Completed

    A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

    PRT1419

    Multiple Myeloma, Acute Myeloid Leukemia +2

    Enrollment
    16
    Start
    Sep 2020
    Primary Completion
    Mar 2022
    Completion
    Mar 2022
    NCT04543305
  • Phase 1
    Completed

    A Study of PRT1419 in Patients With Advanced Solid Tumors

    PRT1419

    Sarcoma, Melanoma +5

    Enrollment
    26
    Start
    Aug 2021
    Primary Completion
    Feb 2023
    Completion
    Feb 2023
    NCT04837677
  • Phase 1
    Terminated

    PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

    PRT1419, Azacitidine

    Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma +8

    Enrollment
    21
    Start
    Mar 2022
    Primary Completion
    Jan 2024
    Completion
    Jan 2024
    NCT05107856
  • Phase 1
    Completed

    A Study of PRT2527 in Participants With Advanced Solid Tumors

    PRT2527

    Sarcoma, Castrate Resistant Prostate Cancer +3

    Enrollment
    30
    Start
    Feb 2022
    Primary Completion
    Dec 2023
    Completion
    Dec 2023
    NCT05159518
  • Phase 1
    Completed

    A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

    PRT3645

    Breast Cancer, Glioblastoma +5

    Enrollment
    22
    Start
    Dec 2022
    Primary Completion
    Jun 2024
    Completion
    Jun 2024
    NCT05538572
  • Phase 1
    Completed

    PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

    PRT3789, Docetaxel

    Advanced Solid Tumor, Metastatic Solid Tumor +2

    Enrollment
    135
    Start
    May 2023
    Primary Completion
    Oct 2025
    Completion
    Oct 2025
    NCT05639751
  • Phase 1
    Completed

    A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

    PRT2527, Zanubrutinib

    Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) +10

    Enrollment
    86
    Start
    Sep 2023
    Primary Completion
    Jun 2025
    Completion
    Jan 2026
    NCT05665530
  • Phase 1
    Terminated

    A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

    PRT7732

    Advanced Solid Tumor, Metastatic Solid Tumor +8

    Enrollment
    42
    Start
    Nov 2024
    Primary Completion
    Jan 2026
    Completion
    Jan 2026
    NCT06560645
  • Phase 1
    Recruiting

    A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

    PRT12396

    Polycythemia Vera (PV), Myelofibrosis (MF) +4

    Enrollment
    100
    Start
    Apr 2026
    Primary Completion
    Apr 2028est.
    Completion
    Apr 2028est.
    NCT07469891
  • Phase 1
    Not yet recruiting

    A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer

    PRT13722, Fulvestrant

    Breast Cancer, Hormone-receptor-positive Breast Cancer +5

    Enrollment
    242
    Start
    Oct 2026est.
    Primary Completion
    Oct 2028est.
    Completion
    Oct 2029est.
    NCT07905001
Search ClinicalTrials.gov for “Prelude Therapeutics”